RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Study Completion Date

2005-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072

Herpes Labialis

COMPLETED PHASE2/PHASE3

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

NCT00129818

Genital Herpes

COMPLETED PHASE4

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

NCT00248144

Recurrent Herpes Labialis

COMPLETED PHASE4

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

NCT00171990

Recurrent Genital Herpes

COMPLETED PHASE3

Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients

NCT00477334

Genital Herpes

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Genital Herpes (RGH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Famciclovir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months.

* Patients with active HSV-2 or HSV-1 infection as confirmed by Polymerase Chain Reaction (PCR).
* Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes

Exclusion Criteria

* • Female patients who are pregnant or breast-feeding.

* Current, history or suspicion of liver disease or kidney disease.
* HIV infected (as confirmed by positive HIV serology).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No